KR102235603B1 - 향상된 이식유전자 발현 및 가공 - Google Patents

향상된 이식유전자 발현 및 가공 Download PDF

Info

Publication number
KR102235603B1
KR102235603B1 KR1020157022393A KR20157022393A KR102235603B1 KR 102235603 B1 KR102235603 B1 KR 102235603B1 KR 1020157022393 A KR1020157022393 A KR 1020157022393A KR 20157022393 A KR20157022393 A KR 20157022393A KR 102235603 B1 KR102235603 B1 KR 102235603B1
Authority
KR
South Korea
Prior art keywords
mar
seq
leu
delete delete
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157022393A
Other languages
English (en)
Korean (ko)
Other versions
KR20150123803A (ko
Inventor
발레리 르 폰
니콜라 멜모드
알렉썽드르 레가메
몽스 부스타
디보하 레이
니암 하라기
카자 코스틸코
피에르-알랭 지호
다비드 칼라브러스
Original Assignee
셀렉시스 에스. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀렉시스 에스. 에이. filed Critical 셀렉시스 에스. 에이.
Publication of KR20150123803A publication Critical patent/KR20150123803A/ko
Application granted granted Critical
Publication of KR102235603B1 publication Critical patent/KR102235603B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020157022393A 2013-02-01 2014-02-01 향상된 이식유전자 발현 및 가공 Active KR102235603B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361759802P 2013-02-01 2013-02-01
US61/759,802 2013-02-01
US201361800244P 2013-03-15 2013-03-15
US61/800,244 2013-03-15
US201361806634P 2013-03-29 2013-03-29
US61/806,634 2013-03-29
PCT/IB2014/000100 WO2014118619A2 (en) 2013-02-01 2014-02-01 Enhanced transgene expression and processing

Publications (2)

Publication Number Publication Date
KR20150123803A KR20150123803A (ko) 2015-11-04
KR102235603B1 true KR102235603B1 (ko) 2021-04-05

Family

ID=50239688

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157022393A Active KR102235603B1 (ko) 2013-02-01 2014-02-01 향상된 이식유전자 발현 및 가공

Country Status (20)

Country Link
US (1) US11898154B2 (cg-RX-API-DMAC7.html)
EP (2) EP2951309B1 (cg-RX-API-DMAC7.html)
JP (1) JP6563816B2 (cg-RX-API-DMAC7.html)
KR (1) KR102235603B1 (cg-RX-API-DMAC7.html)
CN (2) CN120718957A (cg-RX-API-DMAC7.html)
AU (2) AU2014210856B2 (cg-RX-API-DMAC7.html)
CA (1) CA2898878C (cg-RX-API-DMAC7.html)
DK (2) DK2951309T3 (cg-RX-API-DMAC7.html)
ES (2) ES2717175T3 (cg-RX-API-DMAC7.html)
FI (1) FI3536797T3 (cg-RX-API-DMAC7.html)
HU (2) HUE061494T2 (cg-RX-API-DMAC7.html)
IL (1) IL240198B (cg-RX-API-DMAC7.html)
LT (1) LT2951309T (cg-RX-API-DMAC7.html)
PL (2) PL3536797T3 (cg-RX-API-DMAC7.html)
PT (2) PT2951309T (cg-RX-API-DMAC7.html)
RU (1) RU2711505C9 (cg-RX-API-DMAC7.html)
SG (2) SG10201803758XA (cg-RX-API-DMAC7.html)
SI (1) SI2951309T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014118619A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506419B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576269B (zh) * 2014-04-01 2020-08-28 三生国健药业（上海）股份有限公司 一种含mar核心片段的动物细胞表达载体
CN105154473B (zh) * 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
US20180265894A1 (en) * 2015-10-06 2018-09-20 National University Corporation Okayama University Gene Expression Cassette And Product Thereof
JP6871679B2 (ja) * 2016-03-23 2021-05-12 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
JP2017070224A (ja) * 2015-10-06 2017-04-13 国立大学法人 岡山大学 遺伝子発現用カセット及びその産生物
WO2017109177A1 (en) 2015-12-24 2017-06-29 Selexis S.A. Improved eukaryotic cells for protein manufacturing and methods of making them
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
EP3219803A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum für Molekulare Medizin Enhanced sleeping beauty transposons, kits and methods of transposition
WO2017191165A1 (en) * 2016-05-03 2017-11-09 Lonza Ltd Modulation of lipid metabolism for protein production
JP7382138B2 (ja) * 2016-10-03 2023-11-16 第一三共株式会社 Ｈｓｐａ５遺伝子のプロモーター
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2018224162A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for characterizing loss of antigen presentation
JP7240749B2 (ja) * 2017-09-29 2023-03-16 ベスファジェン・インコーポレイテッド 心不全の予防または治療のための医薬組成物
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
CN108504692B (zh) * 2018-03-26 2021-07-23 安徽大学 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用
WO2019219947A1 (en) * 2018-05-18 2019-11-21 Sorbonne Universite Molecular tools and methods for transgene integration and their transposition dependent expression
WO2019246486A2 (en) 2018-06-21 2019-12-26 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
RU2686102C1 (ru) * 2018-08-07 2019-04-24 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Рекомбинантный вектор для создания плазмидных генетических конструкций, обладающих повышенной длительностью экспрессии целевых генов
US20210343368A1 (en) * 2018-09-05 2021-11-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method for Engineering Synthetic Cis-Regulatory DNA
WO2020081537A1 (en) * 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
US20230193341A1 (en) 2018-10-24 2023-06-22 Selexis Sa Expression systems, recombinant cells and uses thereof
HUE068630T2 (hu) 2018-12-10 2025-01-28 Amgen Inc Mutáns PiggyBac transzpozáz
US12404527B2 (en) * 2018-12-24 2025-09-02 Selexs S.A. Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells
US20220088158A1 (en) 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
IT201900002321A1 (it) * 2019-02-18 2020-08-18 Univ Degli Studi Padova Peptidi con attivita' antitumorale
AU2020248453A1 (en) * 2019-03-27 2021-10-28 Phoenix Tissue Repair, Inc. Systems and methods for producing collagen 7 compositions
CN110006866B (zh) * 2019-04-16 2022-04-22 杭州迈尔德生物科技有限公司 一种阿片类活性物质的通用检测方法及其检测试剂盒
WO2020228721A1 (en) * 2019-05-13 2020-11-19 Lin Mei Chun Method and kit for monitoring cancer
EP4041895A1 (en) * 2019-10-10 2022-08-17 The Regents of the University of California Methods to stabilize mammalian cells
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN110863008B (zh) * 2019-11-22 2020-10-16 昆明学院 Mar序列调控弱启动子构建高效表达载体的方法
US20230046668A1 (en) 2019-12-24 2023-02-16 Selexis S.A. Targeted integration in mammalian sequences enhancing gene expression
KR102937659B1 (ko) * 2020-02-19 2026-03-10 우시 바이올로직스 아일랜드 리미티드 강화된 발현 시스템 및 그 사용방법
CN111500629B (zh) * 2020-04-17 2021-11-19 安徽中盛溯源生物科技有限公司 一种高表达层粘连蛋白-511变体的方法及其应用
US20230242936A1 (en) * 2020-05-14 2023-08-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Dual promoter systems
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN113881703B (zh) * 2021-10-11 2022-06-21 中国人民解放军军事科学院军事医学研究院 一种提高cho细胞同源重组效率的方法及其相关产品和应用
CN116440269B (zh) * 2022-01-10 2024-02-09 华中农业大学 Slc35a1基因作为靶点在防治猪流行性腹泻病中的应用
CN114958914B (zh) * 2022-06-06 2023-09-26 新乡医学院 一种人类及哺乳动物细胞附着体表达载体、构建方法和应用
CN115896227A (zh) * 2022-12-20 2023-04-04 西北农林科技大学 一种鉴定外源基因整合位点以增强转基因表达的方法
GB202305637D0 (en) 2023-04-17 2023-05-31 Macomics Ltd Transposons, vectors and genetically engineered cells
GB202415693D0 (en) 2024-10-24 2024-12-11 Macomics Ltd Genetically-engineered cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2011033375A2 (en) * 2009-09-18 2011-03-24 Selexis S.A. Products and methods for enhanced transgene expression and processing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731178A (en) 1990-03-21 1998-03-24 Behringwerke Aktiengesellschaft Attachment-elements for stimulation of eukaryotic expression systems
JP3656277B2 (ja) * 1995-05-17 2005-06-08 味の素株式会社 組換えｄｎａ法によるトランスグルタミナーゼの効率的製造法
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
WO2004065581A2 (en) * 2003-01-15 2004-08-05 Discovery Genomics, Inc. Transposon-insulator element delivery systems
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
KR101269656B1 (ko) 2003-10-24 2013-05-30 셀렉시스 에스. 에이. Ｍａｒ 서열의 복합 트랜스펙션 방법에 의한 포유동물 세포에서의 고효율 유전자 전달 및 발현
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
WO2007021353A2 (en) * 2005-06-10 2007-02-22 Genentech, Inc. Improving antibody expression using vectors containing insulator elements
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
US20090247609A1 (en) 2007-12-20 2009-10-01 Hitto Kaufmann Sm-protein based secretion engineering
WO2010008564A2 (en) * 2008-07-16 2010-01-21 Recombinetics Plaice dna transposon system
EP2417263B1 (en) * 2009-04-09 2015-09-23 ProteoVec Holding L.L.C. Production of proteins using transposon-based vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
WO2011033375A2 (en) * 2009-09-18 2011-03-24 Selexis S.A. Products and methods for enhanced transgene expression and processing

Also Published As

Publication number Publication date
CN120718957A (zh) 2025-09-30
SG11201505487UA (en) 2015-08-28
HUE061494T2 (hu) 2023-07-28
CN105073995A (zh) 2015-11-18
RU2711505C2 (ru) 2020-01-17
WO2014118619A2 (en) 2014-08-07
FI3536797T3 (fi) 2023-03-23
HK1216323A1 (en) 2016-11-04
PL3536797T3 (pl) 2023-09-11
DK3536797T5 (da) 2024-09-02
EP2951309B1 (en) 2019-01-30
IL240198A0 (en) 2015-09-24
DK2951309T3 (en) 2019-04-23
JP6563816B2 (ja) 2019-08-21
EP3536797B1 (en) 2023-01-04
ZA201506419B (en) 2017-02-22
ES2717175T3 (es) 2019-06-19
AU2019250224A1 (en) 2019-11-07
EP3536797A1 (en) 2019-09-11
PT2951309T (pt) 2019-04-03
ES2940433T3 (es) 2023-05-08
AU2014210856B2 (en) 2019-10-24
RU2711505C9 (ru) 2020-08-12
CA2898878A1 (en) 2014-08-07
US20150361451A1 (en) 2015-12-17
DK3536797T3 (da) 2023-04-03
AU2019250224B2 (en) 2022-05-12
CA2898878C (en) 2020-04-28
AU2014210856A1 (en) 2015-07-30
EP2951309A2 (en) 2015-12-09
PL2951309T3 (pl) 2019-06-28
WO2014118619A3 (en) 2014-10-30
SG10201803758XA (en) 2018-06-28
RU2015127667A (ru) 2017-03-06
HUE043103T2 (hu) 2019-08-28
IL240198B (en) 2019-10-31
KR20150123803A (ko) 2015-11-04
SI2951309T1 (sl) 2019-04-30
LT2951309T (lt) 2019-03-25
JP2016504922A (ja) 2016-02-18
US11898154B2 (en) 2024-02-13
PT3536797T (pt) 2023-03-15

Similar Documents

Publication Publication Date Title
AU2019250224B2 (en) Enhanced transgene expression and processing
AU2020274339B2 (en) Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products
AU2022201296B2 (en) Genetically modified cells, tissues, and organs for treating disease
AU2022200903B2 (en) Engineered Cascade components and Cascade complexes
KR102907773B1 (ko) 인간 대상체에서의 비-노화-관련 청각 손상의 치료를 위한 조성물 및 방법
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
KR102799185B1 (ko) 아마이엘로이스로부터의 트랜스포사제를 이용한 핵산 작제물의 진핵세포 게놈으로의 전위
TWI923418B (zh) 用於治療人類個體之非年齡相關性聽力障礙的組成物及方法
KR101476010B1 (ko) 고생산성 세포의 수립을 위한 발현 벡터 및 고생산성 세포
KR20120099376A (ko) 강화된 전이 유전자 발현과 공정 방법 및 그 산물
CN114176043A (zh) 用于治疗疾病的遗传修饰的细胞、组织和器官
TW201207103A (en) DNA element having the activity of enhancing foreign gene expression
CN109790539A (zh) Hspa5基因的启动子
RU2814721C2 (ru) Транспозиция конструкций нуклеиновой кислоты в эукариотические геномы с транспозазой из amyelois
RU2827658C2 (ru) Сконструированные компоненты cascade и комплексы cascade
RU2774631C1 (ru) Сконструированные компоненты cascade и комплексы cascade

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6